← Back to Screener
Dogwood Therapeutics, Inc. Common Stock (DWTX)
Price$1.60
Favorite Metrics
Price vs S&P 500 (26W)-77.83%
Price vs S&P 500 (4W)-54.16%
Market Capitalization$55.45M
All Metrics
Book Value / Share (Quarterly)$2.52
P/TBV (Annual)20.92x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.53
Price vs S&P 500 (YTD)-64.23%
EPS (TTM)$-18.03
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-18.03
EPS (Annual)$-6.88
ROI (Annual)-45.74%
Cash / Share (Quarterly)$0.22
ROA (Last FY)-37.99%
EBITD / Share (TTM)$-6.86
ROE (5Y Avg)-96.25%
Cash Flow / Share (Annual)$-0.53
P/B Ratio0.74x
P/B Ratio (Quarterly)1.65x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-99.42x
ROA (TTM)-36.46%
EPS Incl Extra (Annual)$-6.88
Current Ratio (Annual)2.76x
Quick Ratio (Quarterly)2.13x
3-Month Avg Trading Volume0.07M
52-Week Price Return-55.50%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.20
52-Week High$9.50
EPS Excl Extra (Annual)$-6.88
26-Week Price Return-69.09%
Quick Ratio (Annual)2.13x
13-Week Price Return-42.76%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.76x
Enterprise Value$48.922
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.22
3-Month Return Std Dev89.75%
Net Income / Employee (TTM)$-3
ROE (Last FY)-45.74%
Net Interest Coverage (Annual)-50.78x
EPS Basic Excl Extra (Annual)$-6.88
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-18.03
ROI (TTM)-43.15%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.20
Price vs S&P 500 (52W)-90.59%
Year-to-Date Return-60.10%
5-Day Price Return-11.70%
EPS Normalized (Annual)$-6.88
ROA (5Y Avg)-85.15%
Month-to-Date Return-21.33%
EBITD / Share (Annual)$-6.85
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-96.25%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-18.03
P/TBV (Quarterly)20.92x
P/B Ratio (Annual)1.65x
Book Value / Share (Annual)$2.52
Price vs S&P 500 (13W)-45.62%
Beta1.85x
Revenue / Share (TTM)$0.00
ROE (TTM)-43.15%
52-Week Low$1.54
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DWTXDogwood Therapeutics, Inc. Common Stock | — | — | — | — | $1.60 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Dogwood Therapeutics (formerly Virios Therapeutics) is a development-stage biotech company developing antiviral therapies for conditions associated with abnormal viral-triggered immune responses, including fibromyalgia and long COVID. Its lead candidates—IMC-1, which targets Epstein-Barr virus replication, and IMC-2, a combination of valacyclovir and celecoxib—address the underlying immune dysfunction believed to drive these conditions.